These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6365105)

  • 1. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
    Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs.
    Franceschini G; Poli A; Catapano AL; Gatti E; Sirtori M; Gianfranceschi G; Sirtori CR
    Atherosclerosis; 1981; 40(3-4):245-55. PubMed ID: 7332603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 4. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
    Brook JG; Lavy A; Aviram M; Zinder O
    Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
    Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO
    Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients.
    Dujovne CA; Azarnoff DL; Pentikainen P; Manion CV; Hurwitz A
    Am J Med Sci; 1979; 277(3):255-61. PubMed ID: 222145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral mesoglycan on plasma lipoprotein concentration and on lipoprotein lipase activity in primary hyperlipoproteinemia.
    Postiglione A; De Simone B; Rubba P; Lamenza F; Montefusco S; Mastranzo P
    Pharmacol Res Commun; 1984 Jan; 16(1):1-8. PubMed ID: 6230680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.